NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influen... (p://www.novavax.com target

HOME >> BIOLOGY >> TECHNOLOGY

NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains

Date:4/14/2009

p://www.novavax.com" target="_new">www.novavax.com and in the company's various filings with the Securities and Exchange Commission.

Forward Looking Statement

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding clinical developments, safety, efficacy and potency of our vaccines, and supply availability are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by Novavax to secure and maintain relationships with collaborators; risks relating to the early stage of Novavax's product candidates under development; uncertainties relating to commencing clinical trials and their outcome; risks relating to the supply and commercialization, if any, of Novavax's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; competition for clinical resources and patient enrolment from drug candidates in development by other companies with greater resources and visibility, and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
2. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
3. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
4. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
5. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
6. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
7. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
8. Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
9. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
10. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
11. Novavax CEO to Present at Piper Jaffray 20th Annual Healthcare Conference

Post Your Comments:

(Date:6/19/2013)... (PRWEB) June 19, 2013 Express Diagnostics ... tests, today announced that it has received Class III ... and sell its DrugCheck® NxStep Onsite Drug Screen ... of the rapid screening device in near-patient settings, such ... Screen Cup received Health Canada Class III approval for ...

(Date:6/18/2013)... electric cars could be on roads across North America before ... by the United States Department of Energy, Los Alamos National ... is part of a team led by the Los Alamos ... expensive platinum catalysts in fuel cells. , "One of the ... is the cost of the units. The pure platinum needed ...

(Date:6/18/2013)... (PRWEB) June 18, 2013 (PRWEB) June 18, 2013 ... time and attendance system in North America, has ... shares employee data and payroll records between ExakTime’s ... Plus automates ExakTime software setup and keeps ... imports employee data from a business’ current payroll ...

(Date:6/18/2013)... (PRWEB) June 18, 2013 The human skin ... skin as an important human body part. Similar to the ... in order to function, repair and grow. Recent reports from ... and supplements, is just as important as other life supporting ... to aid in skin cell reproduction, increase the appearance of ...

Breaking Biology Technology:Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2 Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3 US and Canadian researchers drive towards cheaper fuel cells for electric cars 2 ExakTime Introduces AccountLinx Plus 2 Natural Acne Remedies Through Diet, Probiotic Action Shares New Insight on What Foods May Help Lead to Clear Skin 2

[0] Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval [0] US and Canadian researchers drive towards cheaper fuel cells for electric cars [0] ExakTime Introduces AccountLinx Plus [0] Natural Acne Remedies Through Diet, Probiotic Action Shares New Insight on What Foods May Help Lead to Clear Skin

... BARCELONA, February 26 Prous Institute for Biomedical,Research ... its newly,designed website ( http://www.prousresearch.com ). A large ... coverage is being,developed at Prous Institute under the ... President and C.E.O. of the Institute, Dr. ...

... Insmed Inc. (Nasdaq: INSM ), a developer ... conference call on Wednesday, March 11th at 8:30 AM ... quarter and year-end 2008. Insmed intends to issue ... on March 11th.To participate in the live conference call, ...

... 26 NicOx,S.A. (NYSE Euronext Paris: COX) today ... provided an overview of the development and,pre-commercialization activities ... of the signs and symptoms of osteoarthritis (OA). ... Executive Officer of NicOx, commented: "We believe,NicOx has ...

Prous Institute Presents Innovative Approach to Drug Discovery Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value

(Date:6/19/2013)... 19, 2013 MedNet Solutions , a ... management systems, is pleased to announce its participation in ... 23-27 in Boston . This represents ... leader in cloud-based eClinical solutions, has exhibited at this ... iMedNet™ EDC , MedNet,s latest, easy-to-use ...

(Date:6/19/2013)... the most perfectly spherical large objects in nature may ... new study. It appears in ACS, journal Langmuir ... Julyan Cartwright, Antonio G. Checa and Marthe Rousseau point ... have perhaps the most perfectly spherical, or ball-like, shape ... without a microscope. Pearls develop as nacre (mother of ...

(Date:6/19/2013)... fall 2012, the European Medicines Agency (EMA) approved ... first ever gene therapy for clinical use in ... had developed AAV-LPL S447X for the treatment of ... deficiency (LPLD) which affects approximately one or two ... severe, life-threatening inflammations of the pancreas. Afflicted individuals ...

Breaking Biology News(10 mins):MedNet Solutions To Spotlight iMedNet EDC At The 49th DIA Annual Meeting 2 No danger of cancer through gene therapy virus 2

[0] MedNet Solutions To Spotlight iMedNet EDC At The 49th DIA Annual Meeting [0] Pearly perfection [0] No danger of cancer through gene therapy virus

... , WAYNE, Pa., Dec. 14 MODA Technology Partners, ... utility and product testing for the Pharmaceutical industry, today ... third generation mobile data acquisition platform. The latest release ... regulated manufacturing processes. , MODA 3.0 includes the ...

... have resolved a question about how a popular class ... that reveal previously hidden components of chemical communication in ... the illness, people with schizophrenia also struggle to sustain ... that interfere with their ability to hold a job ...

... at The Scripps Research Institute have solved a 10-year-old ... family of enzymes can have two completely distinct roles ... understanding other molecules in the family, the research supplies ... combating diseases including cancer and macular degeneration. The ...

Cached Biology News:MODA Announces Availability of Third Generation Mobile Data Acquisition Platform 2 New biosensors reveal workings of anti-psychotic drugs in the living brain 2 Scripps Research scientists crack mystery of protein's dual function 2 Scripps Research scientists crack mystery of protein's dual function 3

MODA Announces Availability of Third Generation Mobile Data Acquisition Platform New biosensors reveal workings of anti-psychotic drugs in the living brain Scripps Research scientists crack mystery of protein's dual function

...

... clone 41D GenBank Accession Number ... clusterin purified from human serum Formulation: ... and 0.05% sodium azide Quality Assurance: ... HeLa cells or MCF-7 cell lysates. ...

Anti-CoralHue Dronpa Green Monoclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...

Sheep polyclonal to Methaqualone ( Abpromise for all tested applications). Antigen: Methaqualone(5') conjugated to BSA...

Biology Products:

ThermoTWISTER comfort from QUANTIFOIL Instruments Mouse Anti-Human Clusterin alpha chain Monoclonal Antibody, Unconjugated, Clone 41D from Upstate Mouse Anti-Dronpa Green CoralHue Monoclonal Antibody, Unconjugated, Clone 2F6 from MBL International Sheep Anti-Methaqualone Polyclonal Antibody, Unconjugated from Abcam